Rafael Ferreira Coelho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rafael Ferreira Coelho has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
Miguel Srougi
Divisão de Clínica Urológica, Hospital das Clínicas da Faculdade de Medicina da, Universidade de São Paulo, São Paulo, Brazil
7 shared publications- Bernardo Rocco
Department of Urology, Fondazione Policlinico Gemelli Istituto di Ricovero e Cura a Carattere Scientifico-IRCCS, 00168 Rome, Italy
4 shared publications Vipul R. Patel
Department of Urology, AdventHealth Global Robotics Institute, Celebration, FL, United States
4 shared publications- Vipul R. Patel
University of Central Florida College of Medicine, Global Robotics Institiute, Florida Hospital Celebration Health
4 shared publications Giuliano B. Guglielmetti
Sao Paulo State Cancer Institute, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
3 shared publicationsJosé Cury
Department of Urology, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
3 shared publications
Latest Publications
- Open Access
- 6 May 2025
- Published by Elsevier in Pathology - Research and Practice
- Vol. 270, 155997
Infiltrating Natural Killer cells influence the efficacy of BCG immunotherapy in non-muscle-invasive bladder cancer
- 6 May 2025
- Published by Elsevier in Pathology - Research and Practice
- Vol. 270, 155997
Open AccessInfiltrating Natural Killer cells influence the efficacy of BCG immunotherapy in non-muscle-invasive bladder cancer
- 12 March 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (9) , 4311-4319
The presence of prostate MRI-visible lesions at follow-up biopsy as a risk factor for histopathological upgrading during active surveillance
Objective To prospectively determine the ability of visible lesions on multiparametric MRI (PI-RADS 4–5) and commonly used biomarkers to predict disease upgrading on rebiopsy in men with low-risk prostate cancer (PCa) enrolled in active surveillance (AS). Materials and methods For this prospective study, approved by the Institutional Review Board (IRB), we selected consecutive patients with low-risk, low-grade, and localized prostate cancer (PCa) from our active surveillance (AS) program, who were enrolled between March 2014 and December 2020. Patients who had undergone previous prostate surgery, hormonal treatment, had contraindications for mpMRI, or transrectal ultrasound-guided (TRUS) biopsy were excluded from this study. All eligible patients underwent mpMRI at least 3 months after the initial biopsy, followed by MRI-targeted TRUS-guided re-biopsy within 12 months after enrollment. The mpMRI studies were evaluated by an experienced radiologist using the PI-RADS v2 classification. Statistical significance was determined by comparing the results from the MRI with the pathology data from rebiopsy. Results There were 240 patients included. Overall upgrading rate was 41.2% (99/240), higher among patients classified as PIRADS 4 or 5 (77%). MRI sensitivity was 77.7% and specificity was 83.6% on re-biopsy. Visible lesion on mpMRI, PSA density and 3 + /12 positive cores at the first biopsy were good predictors of disease upgrade on rebiopsy. On our predictive model, patients with PI-RADS 4 or 5, PSA density > 0.15 ng/mL/cm3, and 3 + /12 positive cores at first biopsy had 92.4% chance of having clinically significant PCa. Conclusion Patients in AS with PI-RADS 4 or 5 lesions, PSA density > 0.15 ng/mL/cm3 and 3 + /12 positive cores at first biopsy have a high probability of having significant PCa on re-biopsy.
- 12 March 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (9) , 4311-4319
The presence of prostate MRI-visible lesions at follow-up biopsy as a risk factor for histopathological upgrading during active surveillance
Objective To prospectively determine the ability of visible lesions on multiparametric MRI (PI-RADS 4–5) and commonly used biomarkers to predict disease upgrading on rebiopsy in men with low-risk prostate cancer (PCa) enrolled in active surveillance (AS). Materials and methods For this prospective study, approved by the Institutional Review Board (IRB), we selected consecutive patients with low-risk, low-grade, and localized prostate cancer (PCa) from our active surveillance (AS) program, who were enrolled between March 2014 and December 2020. Patients who had undergone previous prostate surgery, hormonal treatment, had contraindications for mpMRI, or transrectal ultrasound-guided (TRUS) biopsy were excluded from this study. All eligible patients underwent mpMRI at least 3 months after the initial biopsy, followed by MRI-targeted TRUS-guided re-biopsy within 12 months after enrollment. The mpMRI studies were evaluated by an experienced radiologist using the PI-RADS v2 classification. Statistical significance was determined by comparing the results from the MRI with the pathology data from rebiopsy. Results There were 240 patients included. Overall upgrading rate was 41.2% (99/240), higher among patients classified as PIRADS 4 or 5 (77%). MRI sensitivity was 77.7% and specificity was 83.6% on re-biopsy. Visible lesion on mpMRI, PSA density and 3 + /12 positive cores at the first biopsy were good predictors of disease upgrade on rebiopsy. On our predictive model, patients with PI-RADS 4 or 5, PSA density > 0.15 ng/mL/cm3, and 3 + /12 positive cores at first biopsy had 92.4% chance of having clinically significant PCa. Conclusion Patients in AS with PI-RADS 4 or 5 lesions, PSA density > 0.15 ng/mL/cm3 and 3 + /12 positive cores at first biopsy have a high probability of having significant PCa on re-biopsy.
- 2 November 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-9
Tumor regression after neoadjuvant hormonal therapy in high risk prostate cancer: pathological outcomes from a randomized phase II trial
Purpose High-risk localized prostate cancer (HRLPC) commonly progresses to metastatic disease after local treatment. Neoadjuvant androgen deprivation therapy (nADT) before radical prostatectomy (RP) has recently been suggested to improve early oncological outcomes in HRLPC. We aimed to perform an exploratory analysis of the pathological outcomes from a prospective trial testing nADT before RP. Methods Prospective, single-centered, phase II, randomized trial performed between October 2018 and July 2021. Random assignment (1:1) for nADT modalities: goserelin (10.8 mg) plus abiraterone acetate (1000 mg/d) plus prednisone (5 mg/d), with or without apalutamide (240 mg/d) for 12 weeks, followed by RP (within 30 days) and extended lymph node dissection. Baseline clinical and pathological variables were assessed in needle biopsies before nADT. Tumor regression was histologically evaluated in surgical specimens using the residual cancer burden index (RCB). Results Sixty-two patients reached the surgical phase. Good response (RCB ≤ 0.25 cm³) was achieved in 14 patients (22.5%). Overall stage migration rate between baseline status (MRI before nADT) and final status (after surgery) was 27.4%. Late stage detection (high tumor burden, perineural invasion) and altered PTEN/ERG immunostatus showed significant association with poor response in univariate analysis. Higher baseline tumor burden was the only independent factor related to poor response in multivariate analysis. Conclusions There are subgroups of patients, such as those with low baseline cancer burden and PTEN/ERG wild-type status, more likely to achieve good response with nADT. In the case of long term oncological benefit to be proven, nADT might be an additional therapeutic resource for these patients.
- 2 November 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-9
Tumor regression after neoadjuvant hormonal therapy in high risk prostate cancer: pathological outcomes from a randomized phase II trial
Purpose High-risk localized prostate cancer (HRLPC) commonly progresses to metastatic disease after local treatment. Neoadjuvant androgen deprivation therapy (nADT) before radical prostatectomy (RP) has recently been suggested to improve early oncological outcomes in HRLPC. We aimed to perform an exploratory analysis of the pathological outcomes from a prospective trial testing nADT before RP. Methods Prospective, single-centered, phase II, randomized trial performed between October 2018 and July 2021. Random assignment (1:1) for nADT modalities: goserelin (10.8 mg) plus abiraterone acetate (1000 mg/d) plus prednisone (5 mg/d), with or without apalutamide (240 mg/d) for 12 weeks, followed by RP (within 30 days) and extended lymph node dissection. Baseline clinical and pathological variables were assessed in needle biopsies before nADT. Tumor regression was histologically evaluated in surgical specimens using the residual cancer burden index (RCB). Results Sixty-two patients reached the surgical phase. Good response (RCB ≤ 0.25 cm³) was achieved in 14 patients (22.5%). Overall stage migration rate between baseline status (MRI before nADT) and final status (after surgery) was 27.4%. Late stage detection (high tumor burden, perineural invasion) and altered PTEN/ERG immunostatus showed significant association with poor response in univariate analysis. Higher baseline tumor burden was the only independent factor related to poor response in multivariate analysis. Conclusions There are subgroups of patients, such as those with low baseline cancer burden and PTEN/ERG wild-type status, more likely to achieve good response with nADT. In the case of long term oncological benefit to be proven, nADT might be an additional therapeutic resource for these patients.
- Open Access
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 523-529
Consensus on Prostate Cancer Treatment of Localized Disease With Very Low, Low, and Intermediate Risk: A Report From the First Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)
PURPOSEA group of international urology and medical oncology experts developed and completed a survey on prostate cancer (PCa) in developing countries. The results are reviewed and summarized, and ...
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 523-529
Open AccessConsensus on Prostate Cancer Treatment of Localized Disease With Very Low, Low, and Intermediate Risk: A Report From the First Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)
PURPOSEA group of international urology and medical oncology experts developed and completed a survey on prostate cancer (PCa) in developing countries. The results are reviewed and summarized, and ...
- 1 February 2021
- Published by Elsevier in European Urology
- Vol. 79 (2) , e47-e49
Reply to Francesco Montorsi, Giorgio Gandaglia, Christoph Würnschimmel, Markus Graefen, Alberto Briganti, and Hartwig Huland’s Letter to the Editor re: Paolo Afonso de Carvalho, João A.B.A. Barbosa, Giuliano B. Guglielmetti, et al. Retrograde Release of the Neurovascular Bundle with Preservation of Dorsal Venous Complex During Robot-assisted Radical Prostatectomy: Optimizing Functional Outcomes. Eur Urol 2020;77:628–35. Incredible Results for Robot-assisted Nerve-sparing Radical Prostatectomy in Prostate Cancer Patients
- 1 February 2021
- Published by Elsevier in European Urology
- Vol. 79 (2) , e47-e49
Reply to Francesco Montorsi, Giorgio Gandaglia, Christoph Würnschimmel, Markus Graefen, Alberto Briganti, and Hartwig Huland’s Letter to the Editor re: Paolo Afonso de Carvalho, João A.B.A. Barbosa, Giuliano B. Guglielmetti, et al. Retrograde Release of the Neurovascular Bundle with Preservation of Dorsal Venous Complex During Robot-assisted Radical Prostatectomy: Optimizing Functional Outcomes. Eur Urol 2020;77:628–35. Incredible Results for Robot-assisted Nerve-sparing Radical Prostatectomy in Prostate Cancer Patients
- Open Access
- 1 January 2021
- Published by Elsevier in Asian Journal of Urology
- Vol. 8 (1) , 27-37
Robot-assisted retroperitoneal lymphadenectomy: The state of art
- 1 January 2021
- Published by Elsevier in Asian Journal of Urology
- Vol. 8 (1) , 27-37
Open AccessRobot-assisted retroperitoneal lymphadenectomy: The state of art
- Open Access
- 1 January 2021
- Published by Elsevier in Asian Journal of Urology
- Vol. 8 (1) , 20-26
Robot-assisted endoscopic inguinal lymphadenectomy: A review of current outcomes
- 1 January 2021
- Published by Elsevier in Asian Journal of Urology
- Vol. 8 (1) , 20-26
Open AccessRobot-assisted endoscopic inguinal lymphadenectomy: A review of current outcomes
- Open Access
- 1 June 2020
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 46 (3) , 434-435
Editorial Comment: Effect of pelvimetric diameters on success of surgery in patients submitted to robot-assisted perineal radical prostatectomy
The outcomes of Radical prostatectomy (RP), regardless of the surgical approach, play an important role on patients' quality of life, mainly due its impact on urinary and sexual function. These outcomes are dependent on multiple factors including patient's anatomy, age, comorbidities, tumor staging, surgeon's experience, nerve sparing approach among others (1-5). Several statistical models have been published trying to predict functional and oncologic outcomes of RP based on patients' factors and perioperative parameters; these models seek to optimize preoperative counseling and patient selection for RP. However, the outcomes of RP are widely variable and conflicting results were reported with regards the importance of each factor as an independent predictor of surgical outcomes (6-11). The truth is that perioperative, functional and oncological results of RP are far more difficult to estimate, and even unknown factors may play an important role on final outcomes. Thus, in daily clinical practice, those prediction models must be cautiously interpreted and shouldn't be used as a unique tool in patients counseling or to select a specific surgical approach. Perineal prostatectomy (RPP) was the first and oldest surgical technique described for prostate cancer treatment, progressively replaced by retropubic prostatectomy (RRP) after the introduction and standardization of the nerve-sparing technique by Walsh (12, 13). As technology and surgical techniques evolved, minimally invasive surgery emerged with laparoscopic (LRP) and robotic-assisted prostatectomy (RARP) presenting shorter length of stay, minimal blood loss and potentially better functional outcomes (14, 15). Recently, RRP was adapted to robotic-assisted platform (P-RARP) and it has been described as an option in patients with previous multiple abdominal surgeries, who presents abdominal wall defect with a mesh, obese or transplanted kidney patients, for example (16, 17). However, the real benefits of this approach in terms of surgical outcomes are yet to be proven. Despite the quite interesting findings described by Yenice at al. (18) in the current study, correlating pelvimetric measurements and operative time (but not with positive surgical margins), this findings happens to be just one more of those inconsistent predictive models with controversial results compared to other series (19, 20) and must have minimal impact on the final decision.
- 1 June 2020
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 46 (3) , 434-435
Open AccessEditorial Comment: Effect of pelvimetric diameters on success of surgery in patients submitted to robot-assisted perineal radical prostatectomy
The outcomes of Radical prostatectomy (RP), regardless of the surgical approach, play an important role on patients' quality of life, mainly due its impact on urinary and sexual function. These outcomes are dependent on multiple factors including patient's anatomy, age, comorbidities, tumor staging, surgeon's experience, nerve sparing approach among others (1-5). Several statistical models have been published trying to predict functional and oncologic outcomes of RP based on patients' factors and perioperative parameters; these models seek to optimize preoperative counseling and patient selection for RP. However, the outcomes of RP are widely variable and conflicting results were reported with regards the importance of each factor as an independent predictor of surgical outcomes (6-11). The truth is that perioperative, functional and oncological results of RP are far more difficult to estimate, and even unknown factors may play an important role on final outcomes. Thus, in daily clinical practice, those prediction models must be cautiously interpreted and shouldn't be used as a unique tool in patients counseling or to select a specific surgical approach. Perineal prostatectomy (RPP) was the first and oldest surgical technique described for prostate cancer treatment, progressively replaced by retropubic prostatectomy (RRP) after the introduction and standardization of the nerve-sparing technique by Walsh (12, 13). As technology and surgical techniques evolved, minimally invasive surgery emerged with laparoscopic (LRP) and robotic-assisted prostatectomy (RARP) presenting shorter length of stay, minimal blood loss and potentially better functional outcomes (14, 15). Recently, RRP was adapted to robotic-assisted platform (P-RARP) and it has been described as an option in patients with previous multiple abdominal surgeries, who presents abdominal wall defect with a mesh, obese or transplanted kidney patients, for example (16, 17). However, the real benefits of this approach in terms of surgical outcomes are yet to be proven. Despite the quite interesting findings described by Yenice at al. (18) in the current study, correlating pelvimetric measurements and operative time (but not with positive surgical margins), this findings happens to be just one more of those inconsistent predictive models with controversial results compared to other series (19, 20) and must have minimal impact on the final decision.
- 1 May 2020
- Published by Elsevier in European Urology
- Vol. 77 (5) , 628-635
Retrograde Release of the Neurovascular Bundle with Preservation of Dorsal Venous Complex During Robot-assisted Radical Prostatectomy: Optimizing Functional Outcomes
- 1 May 2020
- Published by Elsevier in European Urology
- Vol. 77 (5) , 628-635
Retrograde Release of the Neurovascular Bundle with Preservation of Dorsal Venous Complex During Robot-assisted Radical Prostatectomy: Optimizing Functional Outcomes